Opportunities for Increased Drug Sales to the VA

25 May 2016 Publication
Authors: Erin L. Toomey Anna S. Ross

Pharmaceutical manufacturers that produce drugs in non-designated countries under the Trade Agreements Act (TAA) may now have an opportunity to increase their sales to the United States government. The Department of Veterans Affairs (VA) recently announced its new policy to require the listing of “all covered drugs, regardless of country of substantial transformation” on VA Schedule 65 I B, expanding coverage of drugs produced abroad.

The VA’s Federal Supply Schedule (FSS) service supports the health care requirements of the VA and other federal government agencies by making over one million commercial products and services available to federal customers. The VA currently manages multiple award contracts for medical equipment, supply, pharmaceutical, and service Schedule programs. VA Schedule 65 I includes drugs, pharmaceuticals, and hematology related products.

This recent change represents a significant shift in policy. Previously, drugs manufactured in a country with which the United States does not have a trade agreement in place were excluded from Schedule 65 I contracts. The former policy required that all products offered under a VA FSS contract be U.S.-made or substantially transformed, designated country end products under the TAA, meaning that federal customers could not purchase drugs manufactured or substantially transformed in a country such as China, India, or Malaysia. Now, however, the VA can make use of a TAA exception allowing the government to purchase non-TAA-compliant products if no products that comply with the TAA are available, and a VA contracting officer can issue individual non-availability determinations for any drugs covered by Schedule 65 I B that are only available from a non-TAA country.

Although the VA’s announcement provided few details about the procedures for such determinations, and deadlines for listing non-TAA-compliant covered drug products are tight, the change in policy could provide significant government sales opportunities for drug manufacturers that sell non-TAA-compliant products. More information about the Trade Agreement Act requirements and the process for current VA Schedule 65 I B contractors to add drugs and other products to their existing FSS contracts is available here.

__________________________________________________________________

Legal News is part of our ongoing commitment to providing up-to-the-minute information about pressing concerns or industry issues affecting our clients and our colleagues. If you have any questions about this update or would like to discuss this topic further, please contact your Foley attorney or the following:

Erin Toomey
Partner
Detroit, Michigan
313.234.7138
etoomey@foley.com

Anna Ross
Associate
Washington, D.C.
202.295.4132
asross@foley.com 

Related Services

Insights

A Review of Recent Whistleblower Developments
19 July 2019
Legal News: Whistleblower Developments
Cloud security inadequate for Cyber threats, are you surprised?
19 July 2019
Internet, IT & e-Discovery Blog
Blockchain: A Tool With a Future in Healthcare
18 July 2019
Health Care Law Today
Do You Know What IMMEX Stands For?
16 July 2019
Dashboard Insights
Review of 2020 Medicare Changes for Telehealth
11 December 2019
Member Call
2019 NDI Executive Exchange
14-15 November 2019
Chicago, IL
MAGI’s Clinical Research Conference
29 October 2019
Las Vegas, NV
Association for Corporate Counsel Annual Meeting 2019
27-30 October 2019
Phoenix, AZ